menu
    • menu
    [{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ENaC","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chromocell Corporation \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Chromocell Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"CC8464","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chromocell Corporation \/ Maxim Group","highestDevelopmentStatusID":"6","companyTruncated":"Chromocell Corporation \/ Maxim Group"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"CC8464","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Chromocell Corporation","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"","sponsorNew":"Chromocell Corporation \/ Alliance Global Partners","highestDevelopmentStatusID":"4","companyTruncated":"Chromocell Corporation \/ Alliance Global Partners"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Benuvia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Diclofenac","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Chromocell Corporation \/ Chromocell Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Chromocell Corporation \/ Chromocell Corporation"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"CC8464","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Chromocell Corporation","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"","sponsorNew":"Chromocell Corporation \/ Alliance Global Partners","highestDevelopmentStatusID":"4","companyTruncated":"Chromocell Corporation \/ Alliance Global Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Chromocell Corporation

    Menu

    Chromocell Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Benuvia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Benuvia Operations and Chromocell Form Strategic Partnership for Healthcare Solutions

                            Details : The partnership grants Chromocell access to concentrate on the clinical advancement of a sublingual formulation of a Diclofenac spray designed for treating acute pain.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 27, 2024

                            Lead Product(s) : Diclofenac

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Benuvia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CC8464

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Alliance Global Partners

                            Deal Size : $6.6 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Chromocell Therapeutics Closes IPO with Gross Proceeds of $6.6 Million

                            Details : Chromocell intends to use the net proceeds from the proposed offering to support the development of CC8464, which is being evaluated for treating eye pain.

                            Brand Name : CC8464

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 21, 2024

                            Lead Product(s) : CC8464

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Alliance Global Partners

                            Deal Size : $6.6 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CC8464

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Alliance Global Partners

                            Deal Size : $6.6 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

                            Details : Chromocell intends to use the net proceeds from the proposed offering to support the development of CC8464, which is being evaluated for treating eye pain.

                            Brand Name : CC8464

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 16, 2024

                            Lead Product(s) : CC8464

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Alliance Global Partners

                            Deal Size : $6.6 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CC8464

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Maxim Group

                            Deal Size : $0.4 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Chromocell Therapeutics Announce IPO

                            Details : The net proceeds will be used to fund company's continued research and product development of CC8464, an oral, potent, highly selective, peripherally-restricted inhibitor for the treatment of Erythromelalgia.

                            Brand Name : CC8464

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 02, 2023

                            Lead Product(s) : CC8464

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Maxim Group

                            Deal Size : $0.4 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Chromocell Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chromocell Makes Chromovert Technology and Novel Compounds Available to Support COVID-19 Research

                            Details : Chromovert has been successfully used to identify a novel, non-addictive pain blocker that is in clinical development. The company is now making its technology available to the scientific community.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            April 07, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth